SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.72
+6.03%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 7.09x
- Price / sales
- 86.30x
- Price / cash flow
- -37.38x
Enterprise value
- Enterprise value
- $6.8B
- EV / sales
- 75.26x
- EV / EBITDA
- -36.70x
- EV / EBIT
- -33.83x
- Market cap
- $7.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026